<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901041</url>
  </required_header>
  <id_info>
    <org_study_id>2R01AA015923-06</org_study_id>
    <nct_id>NCT02901041</nct_id>
  </id_info>
  <brief_title>Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism</brief_title>
  <official_title>Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University Charles River Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University Charles River Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcoholism is the third leading cause of preventable death in the US, accounting for 80,000&#xD;
      deaths annually. Almost 18 million US adults have alcohol use disorder (AUD); however,&#xD;
      approved medications for the treatment of AUD has shown limited effectiveness.&#xD;
&#xD;
      Zonisamide (ZON), a broad spectrum anticonvulsant, has proven to be more effective than a&#xD;
      placebo in reducing alcohol intake in individuals with alcohol dependence. ZON's mechanism of&#xD;
      action seems to be quite distinct from currently approved anti-alcoholism medications, which&#xD;
      holds promise for treatment of individuals who are not responsive to conventional&#xD;
      medications. However, much remains unknown about ZON's therapeutic mechanisms and ZON's&#xD;
      efficacy in treating patients with a diagnosis of AUD.&#xD;
&#xD;
      To fill in these gaps, the investigators will conduct a double-blind randomized controlled&#xD;
      study that assesses ZON's treatment mechanisms and effectiveness in reducing alcohol&#xD;
      consumption in patients with AUD. Participants will be randomized to one of two conditions:&#xD;
      1) treatment with ZON and a computerized psychotherapy platform called Take Control (TC); 2)&#xD;
      treatment with a placebo (PLC) and TC. To understand the neurobiology behind ZON's potential&#xD;
      therapeutic effects on AUD, fMRI will be used to compare the brain activity of the ZON+TC&#xD;
      versus PLC+TC group while participants perform an alcohol and emotional-word Stroop task, as&#xD;
      well as an alcohol related cues task.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants will complete a telephone and an in-clinic screening to determine&#xD;
      eligibility for this study. Eligible participants will be randomized to receive one of two&#xD;
      treatment conditions: 1) Zonisamide plus Take Control (a computerized alcohol reduction and&#xD;
      medication compliance program developed by the National Institute on Alcohol Abuse and&#xD;
      Alcoholism (NIAAA)); 2) a placebo plus Take Control. For both conditions, participants will&#xD;
      receive 12 treatment sessions. Participants will receive medication at each session, and they&#xD;
      should have two weeks worth of medication on hand at any given time. Participants will take&#xD;
      the medication as prescribed at home. The first 11 treatment sessions will include Take&#xD;
      Control. The 12 treatment sessions will be followed by two drug dose taper sessions, and a&#xD;
      follow up phone interview immediately following the final session.&#xD;
&#xD;
      Participants will also undergo two scans of less than 2 hours duration, one before they begin&#xD;
      study sessions and the second near the end of the study (12th study week and before the&#xD;
      medication taper). At the in-clinic screening session, participants will receive a &quot;MRI&#xD;
      Information for Research Participants&quot; handout that answers some commonly asked questions&#xD;
      about MRI and tells participants what they can expect while undergoing an MRI scan. Both&#xD;
      scans will be conducted at BU CILSE. Participants will be screened before each scan session&#xD;
      for pregnancy (urine sample, women of childbearing potential only), recent smoking or alcohol&#xD;
      use (breathalyzers), and illicit substance use (urine sample). Participants will be asked to&#xD;
      complete the Alcohol Urge Questionnaire (AUQ) before and after the scan. Eligible&#xD;
      participants will complete a 1-hour 3 Tesla MRI scan involving structural imaging (MRI) and&#xD;
      functional imaging (fMRI). The fMRI scans include a resting-state scan (no task involved) a&#xD;
      cognitive (Stroop) task, and an alcohol cue reactivity task. The latter two scans involve&#xD;
      presentation of visual images to participants while they are in the scanner. No contrast&#xD;
      agent or invasive procedures are used. Only personnel trained in working in high magnetic&#xD;
      field environments will work on this project. Imaging data will be analyzed on secure&#xD;
      networks using only encrypted files. All data obtained will be coded to protect participant&#xD;
      privacy and confidentiality.&#xD;
&#xD;
      Starting on March 23, 2020, all study procedures have been moved to HIPAA compliant, remote&#xD;
      platforms and can be performed from home due to the COVID-19 pandemic. Screenings will take&#xD;
      place over the phone or Zoom, neurocognitive assessments will take place on Inquisit 5 at&#xD;
      sessions 1 and 12, female participants of child-bearing potential will be directed to take a&#xD;
      pregnancy test at all sessions, and patients will use a breathalyzer provided by Boston&#xD;
      University at the start of each session to show they are within study-specified limits of&#xD;
      blood alcohol content.&#xD;
&#xD;
      One month following completion of study treatment (study week 16), participants will be asked&#xD;
      to complete a follow-up telephone assessment.&#xD;
&#xD;
      The entire study is estimated to be completed in five years. The first six months to nine&#xD;
      months of the project will be dedicated to hiring, training and certifying staff. Recruitment&#xD;
      will begin within three months of obtaining IRB approval, during Year 1 of the study.&#xD;
      Approximately 3-4 new participants will be recruited per month. We anticipate recruiting a&#xD;
      total of 5 participants in Year 1, 25 participants in Years 2 and 3, 30 participants in year&#xD;
      4, and 15 participants in Year 5. The last third of Year 5 will be devoted to completion of&#xD;
      data entry and data management procedures, preliminary analyses, and the preparation of&#xD;
      manuscripts&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Consumption</measure>
    <time_frame>Change from baseline following 12-week treatment</time_frame>
    <description>Drinking measures derived from Time Line Follow Back data will include the percent days drinking, the number of drinks consumed per day, and the percent days heavy drinking. Heavy drinking will be defined as 4 or more drinks per day for women and 5 or more drinks per day for men.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk Task - Risk Taking Behavior</measure>
    <time_frame>Change from baseline at conclusion of 12-week treatment</time_frame>
    <description>The Risk Task (Rogers et al., 1999) measures decision-making under risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cued Go/No-go Task - Impulsivity</measure>
    <time_frame>Change from baseline at conclusion of 12-week treatment</time_frame>
    <description>The cued go no-go task (Fillmore, 2003) measures impulse control by the ability to inhibit instigated, &quot;prepotent&quot; responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balloon Analogue Risk Task - Risk Taking Behavior</measure>
    <time_frame>Change from baseline at conclusion of 12-week treatment</time_frame>
    <description>The Balloon Analogue Risk Task (BART) is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connors Continuous Performance Task - Impulsivity</measure>
    <time_frame>Change from baseline at conclusion of 12-week treatment</time_frame>
    <description>The Continuous Performance Task (CPT) measures brain damage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Zonisamide &amp; Computerized Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Computerized Psychotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>ZONEGRANÂ® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.</description>
    <arm_group_label>Zonisamide &amp; Computerized Psychotherapy</arm_group_label>
    <other_name>Zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Take Control</intervention_name>
    <description>Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.&#xD;
Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic</description>
    <arm_group_label>Placebo &amp; Computerized Psychotherapy</arm_group_label>
    <arm_group_label>Zonisamide &amp; Computerized Psychotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Zonisamide)</intervention_name>
    <description>Sugar pills manufactured to mimic Zonisamide capsules.</description>
    <arm_group_label>Placebo &amp; Computerized Psychotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-5 diagnosis of an Alcohol Use Disorder (AUD)&#xD;
&#xD;
          -  Adults ages 21 to 65 years old&#xD;
&#xD;
          -  Expressed desire to stop drinking alcohol completely or to reduce alcohol consumption&#xD;
&#xD;
          -  Reported drinking an average of at least 35 standard drinks per week for males, or 28&#xD;
             for females occurring over a 28 consecutive day period during the 90 day-long time&#xD;
             window that preceded the screening session&#xD;
&#xD;
          -  Must be willing to discontinue psychotherapy for substance use disorder (except A.A.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bipolar disorder, schizophrenia, current bulimia/anorexia, dementia, or other&#xD;
             substance use disorder, with the exception of nicotine, marijuana, and caffeine&#xD;
&#xD;
          -  Clear and current suicidal risk&#xD;
&#xD;
          -  Significant medical problem (e.g. uncontrolled diabetes)&#xD;
&#xD;
          -  Medical contraindication to the use of ZON (e.g. history of significant renal disease,&#xD;
             kidney stones, liver problems, metabolic acidosis, etc), as indicated by the FDA&#xD;
             Zonisamide medication guide&#xD;
&#xD;
          -  History of anticonvulsant-induced rash&#xD;
&#xD;
          -  Currently taking:&#xD;
&#xD;
               1. acamprosate, naltrexone, topiramate, disulfiram, or benzodiazepines&#xD;
&#xD;
               2. a medication that is a moderate or major inhibitor or inducer of cytochrome P450&#xD;
                  3A4 enzymes&#xD;
&#xD;
               3. an amphetamine or other psychomotor stimulant&#xD;
&#xD;
               4. opioids or have been treated chronically with opioids&#xD;
&#xD;
               5. antipsychotic agents, anticonvulsants, or sedative hypnotics&#xD;
&#xD;
               6. drugs with &quot;sulfa&quot; moiety (e.g. sulfonamides, sulfonylureas, carbonic anhydrase&#xD;
                  inhibitors, thiazides, and loop diuretics), except ethacrynic acid&#xD;
&#xD;
               7. anxiolytics or antidepressants&#xD;
&#xD;
          -  Previously received ZON for the treatment of an AUD&#xD;
&#xD;
          -  Known allergy to sulfonamides&#xD;
&#xD;
          -  Implantation of anything containing magnetically sensitive material including metal&#xD;
             plates, aneurysm clips, and cardiac pacemakers, stents&#xD;
&#xD;
          -  Non-English speakers&#xD;
&#xD;
          -  Pregnant women or women who are lactating (breastfeeding)&#xD;
&#xD;
        Exclusion from Screening:&#xD;
&#xD;
          -  Reduction in the mean number of drinks consumed per week for the pre-screening period&#xD;
             by 50% or more during the screening period or report of average drinks per day fall&#xD;
             within safe levels of alcohol consumption (i.e. 2 drinks/day for males and 1 drink/day&#xD;
             for females by the HHS standard) two weeks prior to screening&#xD;
&#xD;
          -  Women of child bearing potential (not postmenopausal for at least one year) will not&#xD;
             be admitted into this study unless they are found to have a negative HCG test during&#xD;
             screening. If they pass the HCG screening, they will be asked to maintain the use of&#xD;
             an effective means of contraception during the course of the study&#xD;
&#xD;
          -  Blood test shows lower than average red or white blood cell count or higher than&#xD;
             average level of acid in blood&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Barlow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Anxiety and Related Disorders - Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University Charles River Campus</investigator_affiliation>
    <investigator_full_name>Todd Farchione</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

